(Q36389047)

13 August 2017

Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations (English)

1 reference

13 August 2017

0 references

1 reference

Alec B O'Connor

29

0 references

Edward M. Sellers

object named as

Edward M Sellers

8

0 references

Penney Cowan

15

object named as

Penney Cowan

1 reference

13 August 2017

33

Christine Rauschkolb

1 reference

13 August 2017

35

Cristina Sampaio

1 reference

13 August 2017

3

Robert H Dworkin

1 reference

13 August 2017

6

Richard W Foltin

1 reference

13 August 2017

1

Sandra D Comer

1 reference

13 August 2017

17

J David Haddox

1 reference

13 August 2017

James P Zacny

2

1 reference

13 August 2017

Dennis C Turk

4

1 reference

13 August 2017

George E Bigelow

5

1 reference

13 August 2017

Donald R Jasinski

7

1 reference

13 August 2017

Edgar H Adams

9

1 reference

13 August 2017

Robert Balster

10

1 reference

13 August 2017

Laurie B Burke

11

1 reference

13 August 2017

Igor Cerny

12

1 reference

13 August 2017

Robert D Colucci

13

1 reference

13 August 2017

Edward Cone

14

1 reference

13 August 2017

John T Farrar

16

1 reference

13 August 2017

Jennifer A Haythornthwaite

18

1 reference

13 August 2017

Sharon Hertz

19

1 reference

13 August 2017

Gary W Jay

20

1 reference

13 August 2017

Chris-Ellyn Johanson

21

1 reference

13 August 2017

Roderick Junor

22

1 reference

13 August 2017

Nathaniel P Katz

23

1 reference

13 August 2017

Michael Klein

24

1 reference

13 August 2017

Ernest A Kopecky

25

1 reference

13 August 2017

Deborah B Leiderman

26

1 reference

13 August 2017

Michael P McDermott

27

1 reference

13 August 2017

Charles O'Brien

28

1 reference

13 August 2017

Pamela P Palmer

30

1 reference

13 August 2017

Srinivasa N Raja

31

1 reference

13 August 2017

Bob A Rappaport

32

1 reference

13 August 2017

Michael C Rowbotham

34

1 reference

13 August 2017

Beatrice Setnik

36

1 reference

13 August 2017

Marta Sokolowska

37

1 reference

13 August 2017

Joseph W Stauffer

38

1 reference

13 August 2017

Sharon L Walsh

39

1 reference

13 August 2017

language of work or name

English

0 references

publication date

19 September 2012

1 reference

13 August 2017

1 reference

13 August 2017

153

1 reference

13 August 2017

12

1 reference

13 August 2017

2315-2324

1 reference

Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Abuse liability of oxycodone as a function of pain and drug use history

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Psychopharmacological effects of oxycodone in healthy volunteers: roles of alcohol-drinking status and sex

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Update on abuse-resistant and abuse-deterrent approaches to opioid formulations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Principles of laboratory assessment of drug abuse liability and implications for clinical development

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Methods and results of studying experimental human addiction to the newer synthetic analgesics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Abuse-deterrent opioid formulations: are they a pipe dream?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

The role of human drug self-administration procedures in the development of medications

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Adolescents' motivations to abuse prescription medications.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Motives, diversion and routes of administration associated with nonmedical use of prescription opioids

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Core outcome measures for chronic pain clinical trials: IMMPACT recommendations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Core outcome domains for chronic pain clinical trials: IMMPACT recommendations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Principles of drug abuse liability assessment in laboratory animals

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Principles of initial experimental drug abuse liability assessment in humans

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Guidelines and methodological reviews concerning drug abuse liability assessment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Behavioral pharmacology, drug abuse, and the future

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

A comparison of subjective, psychomotor and physiological effects of a novel muscarinic analgesic, LY297802 tartrate, and oral morphine in occasional drug users

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Assessing the reinforcing properties of drugs.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

The use of choice procedures for assessing the reinforcing properties of drugs in humans

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Performance and physiological measures in abuse liability evaluation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Methods for evaluating addiction liability. (A) "Attitude" of opiate addicts toward opiate-like drugs. (B) a short-term "direct" addiction test.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Identifying appropriate subjects for abuse liability studies using prestudy pharmacological testing.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Choice between money and intranasal heroin in morphine-maintained humans.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Measurement of Recovery from Outpatient General Anaesthesia with a Simple Ocular Test

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Effects of short- and long-term administration of pentazocine in man.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Evaluation of nalbuphine for abuse potential.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

The reinforcing and subjective effects of morphine in post-addicts: a dose-response study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Human drug abuse liability assessment: opioids and analgesics

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Supersensitivity to naloxone following acute morphine pretreatment in humans: behavioral, hormonal and physiological effects.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Addiction liabilities of morphinan, 6-methyldihydromorphine and dihydrocodeinone.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Human methadone self-administration: effects of diazepam pretreatment

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Ethical and practical issues involved in behavioral pharmacology research that administers drugs of abuse to human volunteers.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

Drug discrimination in human postaddicts: agonist-antagonist opioids.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494795

History of abuse liability testing in humans

21 September 2018

1 reference

12 December 2020

Use of miotic effect in evaluating analgesic drugs in man

1 reference

12 December 2020

Drug-induced mood changes in man. I. Observations on healthy subjects, chronically ill patients, and postaddicts

1 reference

12 December 2020

Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts

1 reference

12 December 2020

THE ADDICTION RESEARCH CENTER INVENTORY: APPENDIX. I. ITEMS COMPRISING EMPIRICAL SCALES FOR SEVEN DRUGS. II. ITEMS WHICH DO NOT DIFFERENTIATE PLACEBO FROM ANY DRUG CONDITION

1 reference

12 December 2020

Flicker fusion frequency; background and applications

1 reference

12 December 2020

THE ADDICTION RESEARCH CENTER INVENTORY: STANDARDIZATION OF SCALES WHICH EVALUATE SUBJECTIVE EFFECTS OF MORPHINE, AMPHETAMINE, PENTOBARBITAL, ALCOHOL, LSD-25, PYRAHEXYL AND CHLORPROMAZINE

1 reference

12 December 2020

Development of scales based on patterns of drug effects, using the addiction Research Center Inventory (ARCI)

1 reference

12 December 2020

Research design strategies to evaluate the impact of formulations on abuse liability

1 reference

12 December 2020

Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man

1 reference

12 December 2020

Development of the Addiction Research Center Inventory (ARCI): Selection of items that are sensitive to the effects of various drugs

1 reference

12 December 2020

10.1016/J.PAIN.2012.07.035

Identifiers

DOI

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

22998781

1 reference